Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer

Exclusion Criteria

• •1. Pregnant and/or breastfeeding.
• •2. With active, known or suspected autoimmune diseases or other concurrent immune system diseases.
• •3. Receive systemic cytotoxic chemotherapy or experimental drugs within 4 weeks before the start of neoantigen treatment, excluding EGFR-TKI and anti-angiogenesis targeted drugs.
• •4. Patients participated in other anticancer drug clinical trials within 4 weeks.
• •5. Liver and kidney dysfunction, severe heart disease, coagulation dysfunction, and impaired hematopoietic function.
• •6. Systemic infection.
• •7. Any uncertainties that have an impact on the safety or compliance of the patient.
• •8. Any disease, treatment, abnormal laboratory history or medical history that affects the participant's participation in the entire research process, or the investigator believes that it is not suitable to participate in this study.